Table: Anges -Q1 group results
Apr 23 (Reuters)-
Anges, Inc.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Mar 31, 2018 Mar 31, 2017 Dec 31, 2018
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 73 mln 83 mln 365 mln
(-11.4 pct) (+0.1 pct)
Operating loss 590 mln loss 1.04 loss 2.50
Recurring loss 587 mln loss 1.03 loss 2.50
Net loss 537 mln loss 1.51 loss 2.50
EPS loss 6.67 yen loss 20.89 yen loss 30.75 yen
Ann Div NIL NIL
-Q2 div NIL NIL
-Q4 div NIL NIL
NOTE - Anges, Inc..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4563.T
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001